Global expansion BVBLUE is a CLIA waived rapid sialidase test with broad distribution potential, having sold over 7 million tests worldwide and actively seeking domestic and international expansion opportunities. Target distributors and regional partners in high-volume healthcare settings and fertility/wert programs.

Strategic partnerships The company invites distributors to broaden their assortment, presenting a clear channel for B2B collaboration. Develop outreach to medical distributors, urgent care networks, and hospital procurement teams seeking rapid BV testing solutions.

Market position BVBLUE occupies a niche as a rapid, easy-to-use diagnostic for bacterial vaginosis, potentially appealing to outpatient clinics, women's health practices, and point-of-care settings looking to differentiate with a CLIA waived test.

Growth readiness Revenue is substantive for a small team, indicating strong product-market fit and operational capacity to scale through channel partners. Focus on onboarding partners with training, co-marketing, and logistics support to accelerate adoption.

Digital and analytics Tech stack includes WordPress and Google Cloud, enabling scalable online presence and data insights. Leverage digital marketing with partner co-branding, online education, and analytics to grow distributor inquiries and direct sales.